ASCO: Retesting for HER2 Tumor Status Predicts T-DM1 Impact

posted on Jun 05 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- Retesting patients with metastatic breast cancer to determine if their tumors overexpress HER2 could predict effectiveness of the experimental treatment trastuzumab-DM1 (T-DM1), researchers said here.